2026-04-30T06:56:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/173302024-01-23T20:13:03Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982col_20.500.12105_16983

00925njm 22002777a 4500 dc Papandreou, Christopher author Bullò, Mònica author Tinahones, Francisco José author Martínez-González, Miguel Ángel author Corella, Dolores author Fragkiadakis, Georgios A author López-Miranda, José author Estruch, Ramon author Fitó, Montserrat author Salas-Salvadó, Jordi author 2017-09-02 Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15). At baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P  The rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present. The trial is registered at ISRCTN35739639. Registration date: 5th October 2005. 10.1186/s12986-017-0213-3 1743-7075 Nutrition & metabolism http://hdl.handle.net/10668/11561 28878811 http://hdl.handle.net/20.500.12105/17330 Fatty acid metabolism Hepatic lipotoxicity Metabolomics Non-alcoholic fatty liver disease Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial.